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Abstract
Neuroendocrine tumors (NETs) have historically been subcategorized according to 
histologic features and the site of anatomic origin. Here, we characterize the genomic 
alterations in patients enrolled in three phase 3 clinical trials of NET of different anatomic 
origins and assess the potential correlation with clinical outcomes. Whole-exome and 
targeted panel sequencing was used to characterize 225 NET samples collected in the 
RADIANT series of clinical trials. Genomic profiling of NET was analyzed along with 
nongenomic biomarker data on the tumor grade and circulating chromogranin A (CgA) 
and neuron-specific enolase (NSE) levels from these patients enrolled in clinical trials. 
Our results highlight recurrent large-scale chromosomal alterations as a common theme 
among NET. Although the specific pattern of chromosomal alterations differed between 
tumor subtypes, the evidence for generalized chromosomal instability (CIN) was observed 
across all primary sites of NET. In pancreatic NET, although the P value was not significant, 
higher CIN suggests a trend toward longer survival (HR, 0.55, P = 0.077), whereas in the 
gastrointestinal NET, lower CIN was associated with longer survival (HR, 0.44, P = 0.0006). 
Our multivariate analyses demonstrated that when combined with other clinical data 
among patients with progressive advanced NETs, chromosomal level alteration adds 
important prognostic information. Large-scale CIN is a common feature of NET, and 
specific patterns of chromosomal gain and loss appeared to have independent prognostic 
value in NET subtypes. However, whether CIN in general has clinical significance in NET 
requires validation in larger patient cohort and warrants further mechanistic studies.
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Neuroendocrine tumors (NETs) are a heterogeneous group 
of malignancies originating from neuroendocrine cells 
throughout the body. They are identified most frequently 
in the gastrointestinal (GI) tract (51%), lungs (27%) 
and pancreas (6%) (Yao et  al. 2008). The prognosis and 
treatment of patients with NET are currently based on the 
traditional criteria, including tumor grade, anatomic site 
of origin and tumor stage (Falconi & Partelli 2017). While 
these criteria are broadly associated with the clinical 
outcomes in large epidemiologic studies, they do not 
always accurately predict the clinical course of individual 
patients, nor is it clear that they reflect molecular 
pathogenesis.
Several studies on relatively small sample cohorts 
have characterized the genomic profiles of NET. 
Mutations in the MEN1, DAXX and ATRX genes have 
been previously reported in approximately 60% of 
pancreatic NET (pNET) (Jiao et  al. 2011, Scarpa et  al. 
2017). Scarpa et  al. recently identified less frequent 
mutations in the DNA repair genes MUTYH, CHEK2 
and BRCA2 (Scarpa et al. 2017). Further, it was observed 
that the frequent chromosomal alterations detected by 
single nucleotide polymorphism (SNP) array including 
a group with recurrent pattern of whole chromosomal 
loss, affecting specific chromosomes (1, 2, 3, 6, 8, 10, 
11, 15, 16 and 22) were similar to our study (Scarpa 
et  al. 2017). However, the authors did not report the 
loss of chromosome 21 in the cluster. Frequent loss of 
chromosome 21 has previously been described in detail 
by Nagano et al. (2007). Mutations in MEN1 and other 
genes implicated in chromatin remodeling have been 
reported in bronchial NET (Fernandez-Cuesta et  al. 
2014). On the other hand, in NET of the small intestine 
(SI), recurrent mutations in any genes appear to be rare, 
with mutations in the cyclin-dependent kinase inhibitor 
(CDKN1B) reported in less than 10% of cases (Francis 
et al. 2013).
There are fewer reports exploring the prognostic value 
of broad genomic profiling on disease outcomes of NET. 
Loss of heterozygosity (LOH) in chromosome 18 has been 
previously reported as a potential prognostic biomarker 
in SI NET (Hashemi et al. 2013, Karpathakis et al. 2016). 
Mutations in the MEN1, DAXX and ATRX genes in pNET 
have been shown to be associated with overall survival 
(OS) (Jiao et al. 2011, Marinoni et al. 2014).
At the same time, histologic markers such as tumor 
grade, as well as biochemical markers such as circulating 
levels of chromogranin A (CgA) and neuron-specific 
enolase (NSE) have been long known to be associated with 
disease prognosis in NET, independent of their primary 
site of origin (van Adrichem et al. 2016, Yao et al. 2016b).
To gain a better understanding of the genomic 
landscape of NET, we used a combination of next-
generation sequencing (NGS) strategies to characterize 
225 samples collected in the RADIANT series of clinical 
trials, which were placebo-controlled, phase 3 studies that 
evaluated the efficacy and safety of everolimus in distinct 
types of NET. These trials comprised the RADIANT-2 
and RADIANT-4 trials in the GI and lung, and the 
RADIANT-3 trial in the pNET (Pavel et al. 2011, Yao et al. 
2011, 2016a). Genomic profiling of a large set of tumor 
samples from the three distinct primary sites of origin, 
high-quality nongenomic biomarker data on tumor grade 
and circulating CgA and NSE levels from these patients 
enabled us to comprehensively analyze the clinical utility 
of performing NGS in NET.
Materials and methods
RADIANT trials and NGS patient subgroup
RADIANT-2, RADIANT-3 and RADIANT-4 clinical trials 
of everolimus in advanced NET have been previously 
described (Pavel et al. 2011, Yao et al. 2011, 2016a). Tumor 
samples from a subset of patients in these trials were 
sequenced and analyzed. In total, 225 tumor samples 
were successfully sequenced using NGS on whole-exome 
or targeted cancer panel. Further details on trial designs 
and number of patients from each trial included in this 
analysis are listed in Table  1. Each study protocol and 
associated amendments were reviewed and approved by 
independent ethics committees or institutional review 
boards. All patients included in the present analysis 
consented to evaluation of their archival tumor samples.
DNA extraction and NGS analysis
Tumor DNA was extracted from a 40 µm thick formalin-
fixed, paraffin-embedded (FFPE) tissue section, which had 
been histologically confirmed with a tumor purity of ≥20%. 
Among a total of 225 samples, from which, the evaluable 
NGS data were obtained, 134 libraries were constructed 
with Illumina TruSeq and sequenced at an average 
coverage of 100× using Agilent’s SureSelect XT Human All 
Exon V4 kits on an Illumina HiSeq2500 as 100 base-pair 
paired-end reads. Remaining 91 samples were sequenced 
at a median coverage of 300× on a targeted cancer gene 
https://doi.org/10.1530/ERC-18-0332
https://erc.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.Downloaded from Bioscientifica.com at 05/21/2021 05:51:52PM
via free access




panel containing 242 genes at Foundation Medicine Inc. 
(Cambridge, MA, USA; Supplementary Table 1, see section 
on supplementary data given at the end of this article). 
Tumor DNA preparation, library construction, hybrid 
capture and sequencing were performed as previously 
described (Frampton et  al. 2013). Germline DNA 
matching 46 pNET samples was additionally sequenced 
to 50× on the whole-exome panel. Reads were aligned to 
hg19 using BWA-MEM 0.7.10 (Li 2013) and marked for 
duplicates with Picard 1.130. Single nucleotide variants 
and indels were called with Mutect 1.1.7 (Cibulskis et al. 
2013) and Pindel 0.2.5 (Ye et al. 2009), respectively. The 
normal samples were processed with the same pipeline 
and merged into a pool of normals after variant calling 
using GATK CombineVariants (McKenna et al. 2010).
Somatic genetic alterations were reported after 
filtering the known germline variants present in the 
public databases and filtering the novel variants present 
in the 46 normal samples sequenced in this study. 
Variants were then annotated using SnpEff 4.0 (Cingolani 
et al. 2012). Nucleotide sequence alterations were queried 
against known alterations in the catalog of somatic 
mutations in cancer (COSMIC v70; http://cancer.sanger.
ac.uk/cancergenome/projects/cosmic/) and in the SNP 
database (dbSNP v141; http://www.ncbi.nlm.nih.gov/
snp/). Nonsynonymous sequence alterations recorded in 
COSMIC, but not as common germline in dbSNP, were 
designated as known somatic mutations; deleterious 
mutations (nonsense or frameshift) or mutations at 
splice sites were annotated as likely somatic mutations. 
Finally, the remaining mutations recorded in dbSNP or in 
pool of 46 normal samples, and those with no match in 
either COSMIC or dbSNP, were designated as mutations 
of unknown significance and were excluded in the 
subsequent analyses.
Focal copy number variations were assessed, including 
amplifications (defined as genes with absolute copy 
number ≥6 copies, adjusted for purity and ploidy) and 
bi-allelic deletions. Copy number analysis was performed 
using a targeted cancer panel with copy number tiling 
probes as per the methods described in previous studies 
(Frampton et  al. 2013, Sun et  al. 2014), and on WES 
Table 1 Baseline demographics and disease characteristics.
RADIANT-2: N = 67 (16b) RADIANT-4: N = 93 (31b) RADIANT-3: N = 65 (16b)
Everolimus N (%a) Placebo N (%a) Everolimus N (%a) Placebo N (%a) Everolimus N (%a) Placebo N (%a)
NGS/biomarker cohort 32 (48) 35 (52) 55 (59) 38 (41) 29 (45) 36 (55)
Sex
 Male 14 (21) 16 (24) 19 (20) 21 (23) 17 (26) 22 (34)
 Female 18 (27) 19 (28) 36 (39) 17 (18) 12 (18) 14 (22)
Age
 <65 years 18 (27) 25 (37) 25 (27) 20 (22) 20 (31) 26 (40)
 ≥65 years 14 (21) 10 (15) 30 (32) 18 (19) 9 (14) 10 (15)
Race
 Caucasian 29 (43) 33 (49) 48 (52) 26 (28) 25 (38) 31 (48)
 Black 2 (3) 1 (1) 3 (3) 3 (3) 1 (2) 2 (3)
 Asian – – 3 (3) 7 (8) 3 (5) 3 (5)
 Other 1 (1) 1 (1) 1 (1) 2 (2) – –
Primary/metastatic
 Primary 12 (18) 11 (16) 33 (35) 28 (30) 15 (23) 16 (25)
 Metastatic 20 (30) 24 (36) 22 (24) 10 (11) 14 (22) 20 (31)
Primary site of cancer
 Pancreas – – – – 29 (45) 36 (55)
 Lung 1 (1) 4 (6) 19 (20) 10 (11) – –
 SI – small intestine, jejunum, 
ileum, duodenum, cecum, CUPc
25 (37) 21 (31) 26 (28) 17 (18) – –
 Colorectal – rectum, colon 2 (3) 3 (4) 7 (8) 8 (9) – –
 Other GI tissue – stomach, liver, 
unannotatedd
4 (6) 7 (10) 3 (3) 3 (3) – –
NGS platform
 Targeted panel 21 (31) 16 (24) – – 21 (32) 33 (51)
 Whole-exome 11 (16) 19 (28) 55 (59) 38 (41) 8 (12) 3 (5)
aSample percentage represents the distribution of demographic and disease subgroups among the biomarker patient cohort with NGS data within each 
study; bsample percentage represents the percentage of total study population; cCUP denotes that a search for primary was made but not found, and 
hence, grouped with SI NET; dunannotated grouped with other denotes missing data from case report form.
CUP, cancer of unknown primary; GI, gastrointestinal; NGS, next-generation sequencing; SI NET, small intestinal NET.
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data using a customized copy number analysis tool, 
PureCN (Riester et al. 2016). For the latter, coverage was 
normalized against the pool of normal samples. Samples 
with the available sequencing data and type of NGS panel 
are listed in Table 1.
Mutation rate and CIN score
Mutation rate was calculated only from samples sequenced 
on the whole-exome panel using PureCN (Riester et  al. 
2016). Mutation rate was defined as number of mutations 
predicted to be somatic after adjusting for copy number, 
purity and non-reference mapping biases, normalized by 
the length of callable region (≥30× coverage and mapping 
score ≥10). Only variants in coding regions with allelic 
fraction ≥0.03 were counted. The average estimated 
mutation rate in normal samples was 0.39/Mb and was 
subtracted from the tumor averages to correct mutation 
rates for mosaicism, misclassified variants and remaining 
sequencing artifacts. Chromosomal instability (CIN) 
score was defined as the total chromosome length with 
copy number aberrations normalized by the combined 
total length of chromosome 1–chromosome 22. CIN 
scores were reported between 0 and 1, with CIN score of 
0 indicating no chromosomal aberrations, and CIN score 
of 1 indicating copy number aberrations across the whole 
genome.
Statistical analysis
NET subtypes were defined based on K-means clustering 
of the top three principal components obtained by 
applying the principal component analysis on nonfocal 
copy number aberrations reported by our data processing 
pipeline. Association between clinical features and 
genomic aberrations was assessed using the Fisher’s 
exact test or the Wilcoxon–Mann–Whitney test. Cox 
proportional hazard model and log-rank tests were 
used to assess the association between groups defined 
by genomic biomarkers and clinical outcome. GI NET 
from RADIANT-2 and RADIANT-4 trials were pooled 
together for correlative analysis, and hazard ratios (HRs) 
were estimated using Cox proportional hazard model 
stratified by trial. Prognostic analysis was performed by 
combining patients in all treatment arms and results were 
reported after adjusting for treatment effect. Multivariate 
analysis was performed taking into account other known 
prognostic biomarkers in NET as covariates in the hazard 
model – including primary site of origin, CgA, NSE and 
tumor grade.
Results
Patient demographics and other baseline disease 
characteristics of the patients are listed in Table  1. We 
successfully sequenced archival tumor samples from a 
total of 225 patients, which included 67 patients from 
RADIANT-2 (30%), 65 patients from RADIANT-3 (29%) and 
93 patients from RADIANT-4 (41%) trials. The number of 
analyzed patients included in the treatment and placebo 
arms of the three studies is representative of the overall trial 
population cohort (1:1 for RADIANT-2 and RADIANT-3, 
and 2:1 for the RADIANT-4 study). Furthermore, no 
significant difference between treatment and placebo 
arms was observed in demographics or baseline disease 
characteristics (e.g. sex, age, race and primary tumor site).
All the 65 pNET samples analyzed in this study were 
obtained from patients enrolled in the RADIANT-3 trial, 
providing a large set of pNET with detailed information 
on patient demographics, treatment regimen, circulating 
biomarkers and tumor histology for multivariate analysis 
(Table 1). The number of pNET of primary and metastatic 
origin was comparable (31 (48%) and 34 (52%) unique 
patient samples, respectively, Table  1). Gastrointestinal 
NET (n = 126 samples) and lung NET (n = 34 samples) 
were pooled together from RADIANT-2 and RADIANT-4 
trials, providing a large cohort of tumor samples with 
detailed clinical data available for correlative analysis. 
Gastrointestinal NET were analyzed based on the 
primary site of cancer – SI sites (n = 89 samples from SI, 
ileum, jejunum, cancer of unknown primary, cecum or 
duodenum), colorectal sites (n = 20 samples from either 
rectum or colon) and other GI NET (n = 17 samples from 
a mix of various GI tissues, including stomach, liver and 
unknown primary site of origin; Table 1).
Overall genomic characteristics of NET
The overall mutation rate, defined as the number of 
somatic mutations per Mb of coding region, among 
the broad cohort of NET was low compared with rates 
observed in other malignancies and varied little across 
primary sites. Pancreatic NET and colorectal NET 
displayed the highest average mutation rates (1.16/Mb 
and 1.08/Mb), respectively. SI and lung NET had average 
mutation rates of 0.82/Mb and 0.94/Mb, respectively. All 
NET, however, displayed broad copy number aberrations 
involving multiple chromosomes. The extent of these 
broad copy number aberrations among NET was analyzed 
using a single CIN score, defined as the fraction of total 
chromosome length with copy number aberrations. 
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Among the different primary sites, pNET had the highest 
average CIN (median CIN score = 0.47), while colorectal 
NET were the least chromosomally unstable tumors 
(median CIN score = 0.16). SI and lung NET also displayed 
low median CIN scores in a range similar to colorectal 
NET (0.16 and 0.19, respectively).
Genomic landscape of pNET
MEN1 (43%), DAXX (28%), ATRX (11%), TSC2 (6%) and 
PTEN (5%) were the most frequently mutated genes in 
pNET. Mutations in the DAXX and ATRX were mutually 
exclusive, whereas 60% of DAXX and no ATRX mutation 
were found to coexist with mutations in the MEN1 gene. 
The majority of mutations in the MEN1, DAXX and 
ATRX genes were deleterious (82% of all mutations in 
these three genes were either frameshift indels or small 
nucleotide changes leading to immature stop codon). 
Known MTOR/PI3K pathway genes were mutated in 11% 
of pNET (four patients with TSC2 mutations and three 
with PTEN mutations; Fig. 1B). No significant difference 
in mutation and copy number aberration pattern was 
observed between primary and metastatic pNET.
Only 11 pNET samples (17%) had a reported focal 
copy number loss or amplification >5 copies, and CDKN2A 
and CDKN2B were the only two genes with recurring focal 
copy number aberrations (recurring in >5% of samples). 
However, broad/nonfocal copy number aberrations were 
observed in >95% of pNET, comprising LOH or copy 
number gain at whole chromosome or at arm level in 
one or more chromosomes. Unsupervised clustering of 
nonfocal copy number aberrations suggested the presence 
of three distinct molecular subtypes of pNET characterized 
by chromosomal aberration patterns in two mutually 
exclusive sets of chromosomes; 27 samples in group 1 
displayed LOH in chromosome 1, 2, 3, 6, 8, 10, 11, 15, 16, 
21 and 22; eight samples in group 2 were characterized by 
LOH (with two or more copies of the single chromosome 
allele) in the same set of chromosomes as group 1, along 
with the co-occurring copy number gains in a mutually 
exclusive set of chromosomes comprising chromosome 4, 
5, 7, 9, 12, 13, 14, 17, 18, 19 and 20. Finally, 30 samples in 
group 3 were characterized by relatively few copy number 
abnormalities and absence of any recurring pattern of 
chromosomal gains or loss (Fig. 1A).
The median CIN scores of samples in groups 1, 2 and 3 
were 0.47, 0.94 and 0.15, respectively, based on which, we 
categorized groups 1 and 2 as CIN high subgroup and group 
3 as CIN low subgroup. Among the CIN high subgroups, 
the samples in groups 1 and 2 had LOH in an identical 
set of chromosomes, albeit with multiple copies of the 
same chromosome allele in group 2 samples. Moreover, 
the mutually exclusive set of chromosomes with wild-
type (WT) copy numbers in group 1 display copy number 
gains in group 2 samples, indicating that group 2 pattern 
is likely through whole genome duplications, potentially 
evolved from the samples in group 1. We, therefore, refer 
to group 1 as the CIN high-LOH subgroup and group 2 as 
the CIN high-DUP subgroup.
A strong association was observed between the 
presence of mutations in the MEN1, DAXX and ATRX 
genes and the CIN subgroups. All the samples from the 
CIN high subgroup had mutations in at least one of these 
three genes compared with only ~23% of samples from 
the CIN low group, which harbored such mutations (odds 
ratio, 97.71; P < 9.5 × 10−11 Fisher’s exact test; Fig. 1B). No 
particular difference was evident between CIN high-LOH 
and CIN high-DUP samples in terms of location and type 
of mutations present in MEN1 and DAXX.
Association of genomic alterations with clinical 
outcomes in pNET
We next evaluated whether the CIN-based subgroups or 
mutations in the MEN1, DAXX and ATRX genes in pNET 
were associated with any survival outcomes. We also 
evaluated if these genomic biomarkers have additional 
prognostic value over known prognostic biomarkers in 
pNET such as low baseline circulating CgA and NSE levels 
(Yao et al. 2016b).
Among the three subgroups of pNET, based on CIN 
patterns, patients in the CIN high subgroups (i.e. group 
1-2 together) suggest a trend toward longer median 
OS of 62.6  months, as compared to the median OS of 
37.9  months in patients of the CIN low subgroup (HR, 
0.55; 95% confidence interval (CI), 0.28–1.07; P = 0.077) 
(Fig.  1C and D). Adjusting for baseline circulating CgA 
and NSE levels had a minimal impact on the estimated 
HRs (HR, 0.53; 95% CI, 0.27–1.05; P = 0.068). Further 
exploratory analysis of CIN status among low baseline 
CgA and NSE patients who had better prognosis in NET 
(Yao et  al. 2016b) showed that patients with CIN high 
status may have further extended OS in both the low-
CgA (HR, 0.43; 95% CI, 0.18–1.03; P = 0.0578; Fig. 1C) and 
low-NSE subgroups (HR, 0.6; 95% CI, 0.27–1.33; P = 0.21; 
Fig. 1C). However, due to the limited number of events in 
different groups, statistical significance was not achieved 
for any of these biomarkers. A limited number of patients 
with high-baseline CgA and NSE subgroups precluded 
a similar subgroup analysis of CIN status. Furthermore, 
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no association was observed between CIN subgroups 
and progression-free survival (PFS; HR, 1.32; 95% CI, 
0.73–2.41; P = 0.36).
Mutations in the DAXX and ATRX genes have been 
previously shown to be associated with longer OS in 
pNET, both in the presence and absence of mutations in 
the MEN1 gene (Jiao et al. 2011). In our analysis, patients 
with mutations in at least one of these three genes did 
not demonstrate any meaningful improvement in OS 
compared to patients with WT alleles (HR, 0.71; 95% CI, 
0.36–1.42; P = 0.34; Fig.  1C–E). Similarly, no appreciable 
difference in OS was observed when only the mutation 
status of the DAXX and ATRX genes is taken into account 
(HR, 0.71; 95% CI, 0.35–1.42; P = 0.34).
Figure 1
Genomic landscape of 65 pNET and prognostic analysis of biomarkers of OS from RADIANT-3 trial. (A) Three distinct subgroups of pNET identified from 
unbiased clustering of broad chromosomal copy number gain or loss. The pileup plots show regions of chromosome with copy number aberrations on 
the X-axis and percentage of patients within each subgroup on the Y-axis. (B) Mutation profile of patients within each subgroup of patients. Only genes 
with mutation frequency >5% are displayed. (C) Hazard ratio and median OS in subgroup analysis based on genomic biomarkers. (D) Kaplan–Meier plot 
showing OS among CIN subgroups. (E) Kaplan–Meier plot showing OS among pNET based on mutations status in MEN1, DAXX and ATRX genes. (CIN high 
group comprising CIN high LOH (group 1) and CIN high DUP (group 2) in panel A). CIN, chromosomal instability; CgA, chromogranin A; LOH, loss of 
heterozygosity; MUT, sequence mutation or aberrant copy number; NSE, neuron specific enolase; pNET, pancreatic neuroendocrine tumor; OS, overall 
survival; ULN, upper limit of normal; WT, wild-type.
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Finally, the effect of everolimus on PFS over placebo 
was similar in patients with both high and low CIN 
scores; group CIN high: median PFS, 12.5 vs 5.4 months 
(HR, 0.45; 95% CI, 0.21–1); group CIN low: median 
PFS, 10.8 vs 4.6  months (HR, 0.57; 95% CI, 0.22–1.46), 
consistent to that observed in the overall study population 
(median PFS, 11.0 vs 4.6  months; HR, 0.35; 95% CI, 
0.27–0.45, P < 0.001). Treatment-specific effects in patients 
with PI3K pathway mutations could not be evaluated, as 
six of seven patients with mutations in the PI3K pathway 
genes received placebo. The single everolimus-treated 
patient with a mutation in the PI3K pathway (a frameshift 
mutation leading to premature stop codon in TSC2 gene – 
P1771fs*34+) experienced a PFS of 8.1 months.
Genomic landscape and its association with clinical 
outcomes in lung NET
MEN1 mutations were present in 6 of 34 lung NET samples 
(18%). All six lung NET with MEN1 mutations were loss-of-
function mutations accompanied by LOH in the genomic 
region coding for MEN1 gene, suggesting potentially a 
complete loss of MEN1 function in these patients. No 
other gene was found to be recurrently mutated in lung 
NET; specifically, known MTOR/PI3K pathway genes such 
as MTOR, PIK3CA, PTEN, TSC1/2 and PTEN were not 
found to be mutated in any lung NET samples.
Copy number gain of chromosome 7 was present 
in 41% of lung NET, and LOH in chromosome 3 and 
chromosome 11 were present in 47% of lung NET, 
respectively. Whole chromosome copy number gain/loss 
was also observed in other chromosomes at a lower 
frequency, with arm level or whole chromosome gain or 
LOH/deletion present in <25% of samples. Unsupervised 
clustering of chromosomal aberration patterns identified 
three potential clusters of lung NET with median CIN 
scores of 0.10, 0.21, 0.71 in cluster 1 (N = 19), cluster 2 
(N = 10) and cluster 3 (N = 5), respectively. These clusters 
were broadly classified into CIN high (comprising samples 
in clusters 2 and 3 with median CIN score of 0.27) and 
CIN low (comprising samples in cluster 1 with median 
CIN score of 0.10) subgroups.
We obtained only five lung NET samples from the 
RADIANT-2 trial, and four of these patients received 
treatment in the placebo arm (Table  1). We, therefore, 
excluded lung NET from the RADIANT-2 trial in the 
correlative analysis to avoid study-specific bias. PFS 
was used as the end point for prognostic assessment of 
lung NET, as OS has not yet reached the prespecified 
cutoff in the RADIANT-4 trial population. CIN status 
was not associated with differences in PFS (HR, 0.95; 
95% CI, 0.36–2.51; P = 0.916, Fig.  2B and C). However, 
in our exploratory analysis of the three most frequently 
occurring broad chromosomal aberrations (copy number 
gain of chromosome 7, LOH of chromosome 3 and LOH 
of chromosome 11), LOH in chromosome 3 was found to 
be significantly associated with PFS. Lung NET patients 
with WT chromosome 3 (i.e. heterozygous 2 copy of 
chromosome) displayed more than 2-fold longer median 
PFS along with 80% lower risk of disease progression than 
patients with LOH or deletion in chromosome 3 (median 
PFS of 11.2 vs 3.8 months (HR, 0.19; 95% CI, 0.06–0.56; 
P = 0.003); Fig.  2B and C). This correlation was still 
significant after adjusting for tumor grade and baseline 
circulating levels of CgA and NSE as covariates (HR, 0.24; 
95% CI, 0.08–0.76; P = 0.015). Further subgroup analysis 
of lung NET was not feasible due to small sample size.
Genomic profiling of GI NET
Only a handful of genes were found to be recurrently 
mutated in GI NET. In SI NET, BCOR and CDKN1B were 
among the most frequently mutated genes (5 of 89 and 
4 of 89 samples, respectively). Mutations in both the 
BCOR and CDKN1B genes were mostly loss-of-function 
mutations, with frameshifts resulting in immature stop 
codons in 4 of 5 BCOR mutations and 4 of 4 CDKN1B 
mutations. In colorectal NET, only ATM was found to be 
mutated recurrently (3 of 20 or 15% of the samples).
No recurring focal copy number amplification/loss 
was observed in either SI or colorectal NET. However, 
recurring broad LOH in chromosome 18 was present in 
~50% of SI and colorectal NET and copy number gains 
in chromosomes 4, 5, 14 and 20 were observed in >25% 
of SI NET. K-means clustering of broad copy number 
aberrations identified five distinct clusters in GI NET, 
each defined by a specific set of chromosomal aberration. 
Cluster 1 by LOH in chromosome 18 (N = 75); cluster 2 
by gain in chromosome 5 and chromosome 7 (N = 17); 
cluster 3 by gain in chromosome 4, chromosome 5, 
chromosome 14 and chromosome 20 (N = 18); cluster 4 
by gain in chromosome 4, chromosome 5, chromosome 
7, chromosome 14 and chromosome 20 (N = 13); and a 
smaller cluster 5 comprising three high-ploidy samples 
was identified, displaying copy number gains across most 
of the chromosomes (Fig.  3A). As with lung and pNET, 
these clusters could be broadly dichotomized into CIN 
high or CIN low subgroups: CIN high group comprising 
clusters 2 to 5 with median CIN score of 0.26 and CIN low 
group comprising samples in cluster 1 with median CIN 
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score of 0.06. Mutations or copy number aberrations in 
PI3K pathway genes were present in only 1 of 126 GI NET 
(an SI NET with focal homozygous deletion of the TSC2 
gene in the placebo arm of RADIANT-2).
Association of genomic alterations with clinical 
outcomes in GI NET
GI NET samples from RADIANT-2 and RADIANT-4 were 
analyzed together and HRs were stratified by trial and 
adjusted for treatment and primary site of origin. PFS was 
used for prognostic assessment of GI NET, as OS has not 
yet reached the prespecified cutoff in the RADIANT-4 trial 
population.
When NET from all GI tissues were analyzed as a single 
population, patients in the CIN low group had a significantly 
longer PFS, with a median PFS that was twice as long and a 
56% lower risk of disease progression vs those in the CIN 
high group (median PFS of 17.2  months vs 8.2  months 
(HR, 0.44; 95% CI, 0.28–0.71; P = 0.0006); Figs 3B and 4). CIN 
low status is also prognostic of PFS when SI NET are analyzed 
separately from NET of other GI tissues (Fig. 4).
Figure 2
Genomic landscape of 34 lung NET and correlative analysis of prognostic biomarkers of PFS from RADIANT-2 and RADIANT-4 trials. (A) Three distinct 
subgroups of lung NET identified from unbiased clustering of broad chromosomal copy number gain or loss. (B) Hazard ratio and median PFS in 
subgroup analysis based on genomic biomarkers from lung NET in RADIANT-4 trial. (C) Kaplan–Meier plot showing PFS among CIN subgroups of lung NET 
in RADIANT-4 trial. (D) Kaplan–Meier plot showing PFS among lung NET based on copy number status of chromosome 3 in lung NET in RADIANT-4 trial. 
(CIN high, comprising samples in clusters 2–3 in panel A; CIN low, comprising samples in cluster 1 in panel A). chr, chromosome; CIN, chromosomal 
instability; LOH/DEL, copy number loss; NET, neuroendocrine tumor; PFS, progression-free survival; WT, wild-type.
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Multivariate analysis, taking tumor grade and CgA 
into account as covariates in the hazard model, showed 
that CIN-based subgrouping of GI NET is independently 
prognostic of PFS (HR, 0.48; 95% CI, 0.30–0.78; P = 0.003). 
Further exploratory analysis of the subset of GI NET 
with favorable prognosis based on low tumor grade, low 
baseline CgA or low NSE shows that the CIN low GI NET 
patients in these subgroups still displayed significantly 
longer PFS as compared with the CIN high subgroup (HR, 
0.34 (P = 0.0001) in grade 1; HR, 0.34 (P = 0.01) in low 
CgA; and HR, 0.38 (P = 0.03) in low-NSE subgroups of GI 
NET, respectively; Fig.  4). CIN-based subgroup analysis 
of GI NET with high-baseline CgA also shows a trend 
toward better prognosis in CIN low subgroup, although 
Figure 3
Genomic landscape of 126 NET from gastrointestinal tissues and prognostic analysis of biomarkers of PFS from RADIANT-2 and RADIANT-4 trials. (A) Five 
distinct subgroups of GI NET identified from unbiased clustering of broad chromosomal copy number gain or loss. (B) Kaplan–Meier plot showing PFS 
among CIN subgroups. (C) Kaplan–Meier plot showing PFS among GI NET based on copy number status of chromosome 18. (CIN high group comprising 
groups 2–5 in panel A; CIN low comprising patients in group 1 in panel A). chr, chromosome; CIN, chromosomal instability; GI, gastrointestinal; LOH/DEL, 
copy number loss; NET, neuroendocrine tumor; PFS, progression-free survival; WT, wild-type.
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not statistically significant (HR, 0.55; 95% CI, 0.3–1.0; 
P = 0.05). Further subgroup analysis of CIN status in grade 
2 tumors and high NSE levels was not feasible due to 
the small sample size. In addition, NSE status was only 
available from the RADIANT-4 study, and therefore, only 
a subset of GI NET is reported in subgroup analysis based 
on circulating NSE levels.
LOH in chromosome 18 has been previously 
reported as a potential biomarker of good prognosis in 
SI NET (Hashemi et  al. 2013, Karpathakis et  al. 2016). 
Among the GI NET samples profiled in this study, 
LOH in chromosome 18 was present across all the five 
clusters identified based on copy number aberrations, 
and therefore, provides an alternate mechanism for 
subgrouping GI NET. Gastrointestinal NET with LOH 
in chromosome 18 displayed significantly longer 
median PFS than those with WT chromosome 18 (17.2 
vs 7.4 months (HR, 0.53; 95% CI, 0.33–0.85; P = 0.009); 
Figs 3C and 4). When chromosome 18 status in SI and 
non-SI NET were analyzed separately, non-SI NET with 
WT chromosome 18 displayed the smallest median 
PFS of 4  months among all the subgroups (95% CI, 
2.5–5.8 months; Fig. 4).
Discussion
In this study, we performed genomic profiling on 225 
tumor samples from patients with NET enrolled in the 
RADIANT series of phase 3 clinical trials. Detailed genomic 
profiles together with carefully annotated clinical data 
and patient demographic information from one of the 
largest and most diverse cohort of NET presented a unique 
opportunity to characterize the genomic landscape of 
NET and correlate these findings with clinical outcomes. 
Our data suggest that genomic biomarkers based on broad 
chromosomal aberration patterns in NET may add further 
value to frequently used histopathology and circulating 
protein biomarkers for defining a more accurate prognosis 
of NET in the clinic.
In our analysis, low CIN in GI NET was found 
to be significantly associated with improved PFS and 
Figure 4
Prognostic analysis of genomic and nongenomic 
biomarkers in GI NET from RADIANT-2 and 
RADIANT-4 trials. Hazard ratio was estimated 
using Cox proportional hazard model stratified by 
trial, and median PFS in subgroup analysis based 
on tumor grade, circulating biomarkers (CgA and 
NSE), and genomic biomarkers. CgA, 
chromogranin A; chr, chromosome; CIN, 
chromosomal instability; GI, gastrointestinal; 
LOH/DEL, copy number loss; NET, neuroendocrine 
tumor; NSE, neuron specific enolase; PFS, 
progression-free survival; SI, small intestine; ULN, 
upper limit of normal; WT, wild-type.
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appeared to provide additional prognostic value when 
combined with other nongenomic biomarkers such 
as tumor grade and circulating CgA and NSE. While 
these conclusions are derived only from a small sample 
size and require validation in a larger cohort, the data 
presented here highlights the potential clinical utility of 
genomic profiling in patients with NET from GI tissues. 
In accordance with previously reported results, our data 
highlighted the remarkably low frequency of recurring 
mutations in GI NET. Recurring mutations in BCOR and 
CDNK1B were the only recurring mutations in GI NET. 
While the frequency of CDKN1B mutations seen in our 
patient cohort at 5% was comparable to 8% reported in 
the literature (Francis et al. 2013), recurring mutations in 
BCOR have not been previously reported in SI NET. BCOR 
(BCL-6-interacting corepressor) is a known interaction 
partner of histone deacetylases (HDACs) that plays a 
critical role in maintaining gene expression through DNA 
methylation pathways (Huynh et al. 2000).
Recurring loss-of-function mutations in the MEN1 
gene and frequent LOH in chromosome 3 have been 
previously reported in lung NET (Leotlela et  al. 2003, 
Fernandez-Cuesta et al. 2014). While we did not identify 
any association between PFS and the extent of CIN in 
lung NET, there was a trend toward prolonged PFS among 
patients with LOH in chromosome 3. The small numbers 
of lung NET in this study, however, precludes definitive 
conclusions pending validation with a larger cohort of 
patients.
Genomic analysis of pNET revealed a distinct 
association between recurring mutations in the 
MEN1/DAXX/ATRX genes and CIN patterns in mutually 
exclusive sets of chromosomes. Mutations in the 
MEN1/DAXX/ATRX genes were found to be more 
common in pNET with extensive CIN along with a 
very distinct pattern of LOH and gain in mutually 
exclusive set of chromosomes. This association between 
mutations in the MEN1/DAXX/ATRX genes and a distinct 
pattern of chromosomal aberrations in pNET has not 
been previously reported. However, these results are 
consistent with published reports showing association of 
mutations in MEN1, DAXX and ATRX with higher CIN 
and alternate lengthening of telomeres in different cancer 
types (Lin & Elledge 2003, Mirabello et al. 2010, Heaphy 
et  al. 2011, Lovejoy et  al. 2012). Further mechanistic 
studies are warranted to understand how mutations 
in these genes may be linked to distinct chromosomal 
aberration patterns in pNET. It is likely that CIN in pNET 
is the result of instability related to MEN1/DAXX/ATRX 
mutations. MEN1 has been linked to telomere length and 
DAXX/ATRX mutations lead to alternative lengthening 
of telomeres. The differences in outcome may also reflect 
differences in MEN1-mutated (associated with high CIN) 
vs MEN1-WT oncogenesis of pNET (Mirabello et al. 2010, 
Heaphy et al. 2011).
The three pNET clusters identified in our study 
corresponds to group 1, 2 and 4 in the study conducted by 
Scarpa et al. (2017). While, the group 3 (smallest group), 
consists of a small number of patients with polyploid 
tumors that were not identified in our current analyses 
or prior analyses using different techniques (Nagano 
et al. 2007, Scarpa et al. 2017). The identification of this 
additional small group in Scarpa et  al.’s study could be 
due to the larger number of pNET patients or due to 
differences in the study population (Scarpa et  al. 2017). 
The Karpathakis paper addresses small bowel NET and 
identified three groups, which were similar to our study, 
wherein, a group with chromosome 18 LOH was identified 
(Karpathakis et  al. 2016). Both these studies identified 
the alterations in chromosome 4, 5 and 20. The studies 
seem to have grouped slightly differently based on the 
difference in patterns on whether chromosome 7 or 14 
was involved along with alterations on chromosome 4, 
5 and 20. These may be due to differences in sample size, 
population and how finely the groups were clustered.
Conflicting results have been previously reported with 
regard to prognostic role of mutations in the MEN1, DAXX 
and ATRX genes in pNET. Some studies have suggested a 
longer OS in pNET with mutations in DAXX and ATRX 
genes, while others have reported a significantly shorter 
OS among pNET with the loss of nuclear expression of 
DAXX and ATRX proteins using immunohistochemistry 
(IHC) (Jiao et al. 2011, Marinoni et al. 2014). While our 
data suggest a weak trend toward longer OS in patients 
whose tumors have mutations in MEN1, DAXX or ATRX, 
the observed difference was not statistically significant. 
On the other hand, patients whose tumors were CIN 
high appeared to have longer OS in pNET, although 
this difference also did not reach statistical significance. 
Among patients with favorable prognosis based on low-
circulating CgA and NSE levels, we found that there exists 
a subset of pNET with high CIN, which demonstrates a 
very long OS, enabling a better estimation of disease 
prognosis for clinical decision-making by utilizing 
genomic biomarkers along with other commonly used 
circulating biomarkers in pNET. Our frequent losses of 
chromosome 18 and of chromosome 4, 5 and 20 are 
supported by the observations of Banck et al. (2013).
One puzzling aspect of our data is that the association 
of CIN status with survival was different between tumor 
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subgroups defined by anatomical locations. In GI NET, low 
CIN was associated with longer survival, whereas in pNET, 
low CIN was associated with shorter survival. In lung 
NET, there was no clear correlation between CIN status 
and prognosis. This difference of impact of CIN status on 
survival highlights the different genetic make-up of pNET 
and GI NET. These observations suggest that while CIN 
is a common feature among all NET, it may not by itself 
drive tumor biology and may instead be a reflection of 
diverse underlying defects in chromosomal maintenance 
that underlie the development of NET. The limitation of 
our study was the inability to provide comparison with 
the finer GI NET tumor subsites due to small sample size.
Conclusions
Our analyses highlight that large-scale chromosomal 
gains and deletions are a common feature across all NET 
subtypes and specific patterns of chromosomal gain and 
loss appeared to have independent prognostic value in 
some tumor subtypes. However, whether CIN in general 
has clinical significance in NET requires validation in 
larger patient cohort and warrants further mechanistic 
studies to understand the causes for widespread CIN, 
which was commonly observed in NET.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
ERC-18-0332.
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